Sézary Syndrome
📧 Sign up to get email alerts when something new happens for Sézary Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2014-05-28Clinical Trial Update: In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
An in vitro study from the University of Pittsburgh evaluates immune responses in cutaneous T-cell lymphoma, including Sézary syndrome and m…
-
FDA approval · 2013-07-22FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.
-
CLINICAL_TRIALS trial_result · 2012-07-26Clinical Trial Update: Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome [Phase 3]
A Phase 3 trial evaluating an unspecified human monoclonal antibody for mycosis fungoides and Sézary syndrome has been terminated.
-
CLINICAL_TRIALS trial_result · 2012-06-06Clinical Trial Update: Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome [Phase 2]
Phase 2 trial evaluating interleukin-2 in patients with Mycosis fungoides or Sézary syndrome has been terminated.
-
CLINICAL_TRIALS trial_result · 2012-06-06Clinical Trial Update: Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome [Phase 2]
Phase 2 trial evaluating temozolomide for mycosis fungoides or Sézary syndrome has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-05-30Clinical Trial Update: Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome [Phase 2]
Phase 2 trial update examining tretinoin for treating mycosis fungoides and Sézary syndrome has completed.
-
FDA label_change · 2011-05-16FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for TARGRETIN (bexarotene) from Bausch Health US, LLC.
-
FDA approval · 2009-11-05FDA Approved: ISTODAX — Original Application (Celgene Corporation)
The FDA granted original approval for ISTODAX (romidepsin) to Celgene. The approval covered treatment for cutaneous T-cell lymphoma, includi…
-
CLINICAL_TRIALS trial_result · 2008-03-05Clinical Trial Update: Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients [Phase 4]
A Phase 4 clinical trial of ONTAK (denileukin diftitox) in cutaneous T-cell lymphoma patients (including mycosis fungoides and Sézary syndro…
-
CLINICAL_TRIALS trial_result · 2007-04-03Clinical Trial Update: Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome [Phase 2]
A Phase 2 clinical trial is evaluating alemtuzumab for advanced mycosis fungoides and Sézary syndrome, with current status not specified.